Genotoxicity usually referred as adverse effects of a chemical on genetic material via any of a variety of mechanisms, including mutation. Genotoxicity testing is very crucial to perform to determine potential carcinogenic/mutagenic compounds that can cause genetic alterations in somatic or germ cells, and this information is used in regulatory decision-making. Mutagenicity (gene mutation and structural and numerical chromosomal alterations) is one of six basic testing areas that have been adopted by the Organization for Economic Co-operation and Development (OECD, 2011) as the minimum required to screen high-production volume chemicals in commerce for toxicity.
We provide a combination of tests to assess three major end-points of genetic damage associated with human disease: a) gene mutation (i.e. point mutations or deletions/insertions that affect single or blocks of genes) b) clastogenicity (i.e. structural chromosome changes); and c) aneuploidy (i.e. the occurrence of one or more extra or missing chromosomes, leading to an unbalanced chromosome complement).
Aurigene Pharmaceutical Services is
that provides contract research, development and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.